STAT November 14, 2025
Fyodor Urnov

A new FDA proposal would bring breakthrough treatment to countless families that need it

In May, news broke of a biomedical first: the on-demand design and clinical use of a personalized gene editor for a baby boy born with a rare, severe genetic condition. At the STAT Summit in October, the child’s treating physician from the Children’s Hospital of Philadelphia (CHOP) and the lead on developing the gene editor for him shared the stage with him and his parents. The video of a happily squirming 1-year-old brought tears of joy to the eyes of many.

A sobering reminder of the long road ahead toward more such videos was shared in these pages by Celena Lozano, whose son lives with a...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
AI Model FDA-Cleared to Triage 14 Conditions
The Promise And Perils Of FDA’s New ‘Plausible Mechanism’ Pathway (Part 2)
FDA Updates Two Digital Health Final Guidance Documents
FDA in Flux — January 2026 Newsletter
The Promise And Perils Of FDA’s New ‘Plausible Mechanism’ Pathway (Part 1)

Share Article